[A prospective clinical trial of TCD-induced regimen for symptomatic Waldenström macroglobulinemia]

Zhonghua Xue Ye Xue Za Zhi. 2023 Aug 14;44(8):680-683. doi: 10.3760/cma.j.issn.0253-2727.2023.08.012.

[Article in Chinese]

Authors

Y S Huang¹, W J Xiong¹, Y Yu¹, Y T Yan¹, T Y Wang¹, R Lyu¹, W Liu¹, G An¹, Y Z Zhao¹, D H Zou¹, L G Qiu¹, S H Yi¹

Affiliation

¹ State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China.

PMID: 37803844
PMCID: PMC10520223
DOI: 10.3760/cma.j.issn.0253-2727.2023.08.012

No abstract available

MeSH terms

Humans
Prospective Studies
Waldenstrom Macroglobulinemia*

Grants and funding

基金项目：中国医学科学院医学与健康科技创新工程（2022-I2M-1-022、2021-I2M-C&T-B-081）；国家自然科学基金（81970187、82170193、81900203）